Status:
COMPLETED
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
Lead Sponsor:
Novartis
Conditions:
Essential Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study tested the safety of the combination of aliskiren/amlodipine/hydrochlorothiazide in participants with essential hypertension.
Eligibility Criteria
Inclusion
- Outpatients 18 years of age or older
- Male or female participants are eligible.
- Mean sitting diastolic blood pressure (msDBP) and mean sitting systolic blood pressure (msSBP) Requirements:
- For newly diagnosed/untreated participants, msDBP ≥ 100 and \< 120 millimeters of mercury (mmHg), and/or msSBP ≥ 160 and \< 200 mmHg at Visit 1 and Visit 2.
- For previously treated participants, msDBP ≥ 100 and \< 120 mmHg, and/or msSBP ≥ 160 and \< 200 mmHg at Visit 2, Visit 3, or Visit 4.
- For participants requiring tapering off their previous antihypertensive medication, they must meet the above criteria and completely discontinue all antihypertensive treatment prior to entering the treatment phase of the study.
- Participants who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent).
Exclusion
- Inability to discontinue all prior antihypertensive medications safely for a period of 1 week to 4 weeks as required by the protocol.
- Participants on three antihypertensive drugs with msDBP ≥ 110 mmHg and/or msSBP ≥ 180 mmHg at Visit 1.
- Participants on four or more antihypertensive drugs at Visit 1.
- Participants with an msSBP ≥ 200 and msDBP ≥ 120 mmHg anytime during the washout period of the study Visit 1-4 must be discontinued from the study.
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (\>= 5 milli-international units per milliliter mIU/mL).
Key Trial Info
Start Date :
June 5 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 5 2009
Estimated Enrollment :
564 Patients enrolled
Trial Details
Trial ID
NCT00667719
Start Date
June 5 2008
End Date
October 5 2009
Last Update
June 7 2021
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Site
Houston, Texas, United States
2
Investigative Site
Belgium, Belgium
3
Investigative Site
Egypt, Egypt
4
Investigative Site
Germany, Germany